2020-11-13T13:17:49-06:00 2019-12-31 520959934 ELLIN & TUCKER CHARTERED 400 EAST PRATT ST SUITE 200 BALTIMORE MD 21202 990 2019-01-01 521290067 KERALINK INTERNATIONAL INC KERA 8006081193 300 E LOMBARD STREET NO 1510 BALTIMORE MD 21202 SHELBY TYLER CONTROLLER 8006081193 2020-11-13 1 SUSAN KELLER P00245169 4107275735 2020-11-12 65.246.120.254 2020-11-13 10:10:40 ES P AB7DFB60C93AA1B331567231D7D48371795C5F56 E888BF6778F54DE846B1F2C9A21FF77184BE6978 2019 2021-01-29 14:40:06Z SHELBY TYLER 300 E LOMBARD STREET NO 1510 BALTIMORE MD 21202 23415946 0 X HTTPS://KLIVISION.ORG X 1983 MD TO DEVELOP AND IMPLEMENT INNOVATIVE PROGRAMS, PRODUCTS, AND SERVICES TO ELIMINATE CORNEAL BLINDNESS OUTSIDE THE UNITED STATES IN LOW AND MIDDLE-INCOME COUNTRIES. X 10 9 113 0 0 0 317230 14324 14980728 2484959 328464 15369695 48750 0 15675172 17868978 0 2241 0 0 7740680 3463272 0 0 293465 12618621 3400284 20359301 6865797 -4684129 11003181 17964000 27401351 8437814 5238781 9526186 22162570 X TO DEVELOP AND IMPLEMENT INNOVATIVE PROGRAMS, PRODUCTS, AND SERVICES TO ELIMINATE CORNEAL BLINDNESS OUTSIDE THE UNITED STATES IN LOW AND MIDDLE-INCOME COUNTRIES. 0 1 3666011 2241 2484959 MEDICAL SERVICES OF EYE AND TISSUE BANKING INCLUDING THE RECOVERY, PROCESSING, ANAYLSIS, RESEARCH, TESTING, AND DISTRIBUTION OF DONATED OCULAR TISSUES - JANUARY 2019 TO FEBRUARY 2019. 1020098 DEVELOPMENT AND IMPLEMENTATION OF INNOVATIVE PROGRAMS, PRODUCTS, AND SERVICES TO ELIMINATE CORNEAL BLINDNESS OUTSIDE THE US IN LOW AND MIDDLE-INCOME COUNTRIES - MARCH 2019 TO DECEMBER 2019. 4686109 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 46 0 1 113 1 0 0 0 0 0 0 0 0 0 0 X 10 9 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AR CA CO CT FL IL KS ME MD MA MI MN MS MO NH NM ND OH OK OR PA RI SC TN UT VA WV WI NC GA HI NJ X THE ORGANIZATION 8006081193 300 E LOMBARD STREET NO 1510 BALTIMORE MD 21202 C RANDALL MILLS DIRECTOR 1.00 X 0 0 0 ROBERTO PINEDA II MD DIRECTOR 1.00 X 0 0 0 ELLEN KOO MD DIRECTOR 1.00 X 0 0 0 C THOMAS VANGSNESS JR MD DIRECTOR 1.00 X 0 0 0 BRYAN VOSSEKUIL DIRECTOR 1.00 X 0 0 0 SAMUEL C YIU MD DIRECTOR 1.00 X 0 0 0 PAMELA HALL DIRECTOR/ VICE CHAIRMAN 40.00 X X 0 0 0 HARRY CARMITCHEL CHAIRMAN 1.00 X X 0 0 0 DOUGLAS J FURLONG VICE CHAIRMAN, CEO/PRESIDENT 40.00 X X 481656 0 0 MARK JENSEN DIRECTOR 1.00 X 0 0 0 JOHN F MILLER CFO, TREASURER/SECRETARY 40.00 X 254873 0 0 REBECCA JORGENSON COO TREASURER/SECRETARY 40.00 X 227604 0 0 SHELBY TYLER TREASURER 40.00 X 154707 0 0 LINDSAY DENMARK SECRETARY 40.00 X 68770 0 0 CONNIE JONES VP QUALITY REGULATORY & CO 40.00 X 162871 0 0 NANCY CAPLAN DIRECTOR OF HR 40.00 X 160603 0 0 1511084 0 0 6 0 1 0 NEW ENGLAND DONOR SERVICES 60 FIRST AVENUE WALTHAM MA 02451 TISSUE PROCUREMENT 273600 DONOR NETWORK WEST 12667 ALCOSTA BLVD STE 500 SAN RAMON CA 94583 TISSUE PROCUREMENT 228695 THE LIVING LEGACY FOUNDATION 1730 TWIN SPRINGS ROAD SUITE 200 BALTIMORE MD 21227 TISSUE PROCUREMENT 166250 3 14324 14324 REIMUB TISSUE HANDLING 900099 2240740 2240740 MANAGEMENT FEE 561000 244219 244219 2484959 648186 648186 20268477 5546968 14721509 14721509 14721509 17868978 2484959 0 15369695 X 2241 2241 1187610 561146 551051 75413 1356433 1272922 46153 37358 477396 199509 245823 32064 232059 59615 159530 12914 209774 87667 108017 14090 84003 52135 28191 3677 69704 29129 35893 4682 34319 14342 17672 2305 742298 695979 32175 14144 554923 473356 68455 13112 62816 26950 31728 4138 198302 82872 102111 13319 138148 123833 13581 734 88793 69627 17148 2018 325046 135840 167374 21832 97846 40891 50383 6572 DISPOSAL OF ASSETS 512218 420018 92200 AFFILATE VG COSTS 227947 227947 0 0 TUDOR PROJECT EXPENSES 82979 34677 42729 5573 BAD DEBT 69057 28860 35559 4638 111885 46553 40450 24882 6865797 4686109 1886223 293465 331810 325913 2441723 39991 7785498 388296 0 122737 31160 439500 264594 6632959 174906 7852902 18894032 149851 149851 43722 0 17964000 27401351 6625812 5122943 1812002 115838 8437814 5238781 X 9516186 22152570 10000 10000 9526186 22162570 17964000 27401351 11003181 1633203 0 X X 0 1 X 0 0 X 40134 44626 292918 317230 14324 709232 27068296 8268683 15700639 14980728 2484959 68503305 27108430 8313309 15993557 15297958 2499283 69212537 0 2287893 2125382 1399028 306833 6119136 2287893 2125382 1399028 306833 6119136 63093401 20752 452 249389 221085 648186 1139864 20752 452 249389 221085 648186 1139864 45955 106 433700 48750 268477 796988 27175137 8313867 16676646 15567793 3415946 71149389 0.88680 0.70130 0.01600 0.00430 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 439500 264594 174906 174906 DUE TO AFFILIATE 73204 DEFERRED RENT 14095 CUSTOMER DEPOSITS 28539 115838 X 2100211 1215495 1215495 884716 27244 16957018 16984262 17868978 2460998 0 2460998 27244 4377555 4404799 6865797 PART X, LINE 2: KERALINK IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. IN ADDITION, THE INTERNAL REVENUE SERVICE HAS DETERMINED KERALINK IS NOT A PRIVATE FOUNDATION WITHIN THE MEANING OF SECTION 509(A) OF THE CODE. KERALINK FOLLOWS THE PROVISIONS OF ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES UNDER THE INCOME TAXES TOPIC OF THE CODIFICATION. THE CODIFICATION REQUIRES THE EVALUATION OF TAX POSITIONS, WHICH INCLUDE MAINTAINING ITS TAX-EXEMPT STATUS AND THE TAXABILITY OF ANY UNRELATED BUSINESS INCOME, AND DOES NOT ALLOW RECOGNITION OF TAX POSITIONS WHICH DO NOT MEET A "MORE-LIKELY-THAN-NOT" THRESHOLD OF BEING SUSTAINED BY THE APPLICABLE TAX AUTHORITY. MANAGEMENT DOES NOT BELIEVE IT HAS TAKEN ANY TAX POSITIONS THAT WOULD NOT MEET THIS THRESHOLD. PART XI, LINE 4B - OTHER ADJUSTMENTS: REVENUE REPORTED ON PRIOR YEAR FINANCIAL STATEMENT PART XII, LINE 4B - OTHER ADJUSTMENTS: EXPENSES REPORTED ON PRIOR YEAR FINANCIAL STATEMENT PART XI LINE 4B IN FEBRUARY 2019 KERALINK INTERNATIONAL, INC. SOLD ITS U.S. BASED CORNEAL OPERATIONS AND RELATED ASSETS TO CORNEAGEN. AS SUCH, THE PRIOR YEAR AUDITED FINANCIAL STATEMENTS FOR KERALINK INTERNATIONAL, INC. WERE PREPARED FOR THE FOURTEEN MONTH PERIOD FROM JANUARY 2018 THROUGH FEBRUARY 2019. PART XII LINE 4B IN FEBRUARY 2019 KERALINK INTERNATIONAL, INC. SOLD ITS U.S. BASED CORNEAL OPERATIONS AND RELATED ASSETS TO CORNEAGEN. AS SUCH, THE PRIOR YEAR AUDITED FINANCIAL STATEMENTS FOR KERALINK INTERNATIONAL, INC. WERE PREPARED FOR THE FOURTEEN MONTH PERIOD FROM JANUARY 2018 THROUGH FEBRUARY 2019. 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES EYE TISSUE BANKING 38800 EUROPE 0 0 PROGRAM SERVICES EYE TISSUE BANKING 16530 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES EYE TISSUE BANKING 47800 SUB-SUHARAN AFRICA 0 0 PROGRAM SERVICES EYE TISSUE BANKING 2905 SOUTH ASIA 0 0 PROGRAM SERVICES EYE TISSUE BANKING 12100 0 0 0 0 0 0 118135 0 118135 0 0 0 0 0 0 PART I, LINE 3: THE ACCOUNTING SYSTEM USED DOES NOT TRACK EXPENDITURES BY REGION; THEREFORE, THE AMOUNTS LISTED IN PART I LINE 3 ARE ESTIMATES WHICH IN AGGREGATE ARE THE TOTAL OF INTERNATIONAL PROGRAM EXPENSES. PART III ACCOUNTING METHOD: X X X X X X 0 0 0 0 0 0 0 0 0 DOUGLAS J FURLONG VICE CHAIRMAN, CEO/PRESIDENT 380000 0 71250 0 30406 0 0 0 0 0 481656 0 0 0 JOHN F MILLER CFO, TREASURER/SECRETARY 60577 0 108750 0 85546 0 0 0 0 0 254873 0 0 0 REBECCA JORGENSON COO TREASURER/SECRETARY 121154 0 83750 0 22700 0 0 0 0 0 227604 0 0 0 SHELBY TYLER TREASURER 107500 0 30500 0 16707 0 0 0 0 0 154707 0 0 0 CONNIE JONES VP QUALITY REGULATORY & CO 37692 0 0 0 125179 0 0 0 0 0 162871 0 0 0 NANCY CAPLAN DIRECTOR OF HR 119327 0 30000 0 11276 0 0 0 0 0 160603 0 0 0 CORNEAL OPERATIONS AND RELATED ASSETS 2019-03-01 7749435 THIRD PARTY FAIR VALUE ANALYSIS WAS CONDUCTED. 813385370 CORNEAGEN INC 1200 6TH AVENUE SUITE 300 SEATTLE WA 98101 CORPORATION 0 0 0 0 FORM 990, PART III, LINE 3 IN FEBRUARY 2019 KERALINK INTERNATIONAL, INC. SOLD ITS U.S. BASED CORNEAL OPERATIONS AND RELATED ASSETS TO CORNEAGEN. PRIOR TO THE SALE, THE ORGANIZATION'S MISSION WAS TO RELIEVE HUMAN SUFFERING BY FACILITATING THE DONATION, RETRIEVAL, PROCESSING, AND EQUITABLE DISTRIBUTION OF OCULAR TISSUE FOR TRANSPLANTATION, RESEARCH, EDUCATION, AND OTHER MEDICAL NEEDS WORLDWIDE. GOING FORWARD, THE ORGANIZATION WILL BE FOCUSED EXCLUSIVELY ON DEVELOPING AND IMPLEMENTING INNOVATIVE PROGRAMS, PRODUCTS, AND SERVICES TO ELIMINATE CORNEAL BLINDNESS OUTSIDE THE U.S. IN LOW AND MIDDLE-INCOME COUNTRIES (LMICS). FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM AND REVIEWED BY THE CONTROLLER BEFORE FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C PROCESS FOR MONITORING THE CONFLICT OF INTEREST POLICY: ALL NEW EMPLOYEES OF THE ORGANIZATION ARE REQUIRED TO REVIEW AND ACKNOWLEDGE COMPLIANCE WITH THE ORGANIZATION'S CONFLICT OF INTEREST POLICY. OFFICERS, DIRECTORS, AND KEY EMPLOYEES OF THE ORGANIZATION ARE REQUIRED ANNUALLY TO REVIEW AND AFFIRM COMPLIANCE WITH THE POLICY. OFFICERS AND DIRECTORS ARE EXPECTED TO REPORT ANY ACTUAL OR POTENTIALLY MATERIAL CONFLICTS TO THE FULL BOARD OF DIRECTORS FOR REVIEW AND ACTION. ADDITIONALLY ACTUAL OR POTENTIAL CONFLICTS IDENTIFIED ON BEHALF OF ANY KERALINK INTERNATIONAL'S EMPLOYEE WILL BE COMMUNICATED TO EXECUTIVE MANAGMENT FOR INVESTIGATION AND RESOLUTION. FORM 990, PART VI, SECTION B, LINE 15 PROCESS FOR DETERMINING TOP MANAGEMENT OFFICIAL COMPENSATION: THE BOARD OF DIRECTORS SETS THE CEO'S COMPENSATION, WHICH IS MEMORIALIZED IN THE CEO'S EMPLOYMENT CONTRACT. THIS INCORPORATES COMPENSATION SURVEY DATA, REVIEW OF FORM 990 FROM COMPANIES IN RELATED INDUSTRIES AND OF SIMILAR SIZE. MEASUREMENT OF BOARD-SET PERFORMANCE OBJECTIVES ARE ALSO USED TO SET CEO'S ANNUAL COMPENSATION. THE ORGANIZATION'S CEO IS RESPONSIBLE FOR SETTING AND REVIEWING THE COMPENSATION OF KERALINK INTERNATIONAL, INC.'S SENIOR MANAGEMENT TEAM. MARKET COMPENSATION DATA, INDEPENDENT COMPENSATION ANALYSIS AND INDIVIDUAL PERFORMANCE AGAINST OPERATIONAL OBJECTIVES ARE ALL FACTORED INTO THE REVIEW. FORM 990, PART VI, SECTION C, LINE 19 DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G CONSULTING: PROGRAM SERVICE EXPENSES 86,149. MANAGEMENT AND GENERAL EXPENSES 26,942. FUNDRAISING EXPENSES 10,473. TOTAL EXPENSES 123,564. ADP FEES: PROGRAM SERVICE EXPENSES 4,127. MANAGEMENT AND GENERAL EXPENSES 5,084. FUNDRAISING EXPENSES 663. TOTAL EXPENSES 9,874. PROFESSIONAL SERVICES MEDICAL: PROGRAM SERVICE EXPENSES 605,703. MANAGEMENT AND GENERAL EXPENSES 149. FUNDRAISING EXPENSES 3,008. TOTAL EXPENSES 608,860. FORM 990 PART XII THE ORGANIZATION'S U.S. BASED CORNEAL OPERATIONS AND RELATED ASSETS WERE SOLD IN FEBRUARY 2019; AS SUCH, THE AUDITED FINANCIAL STATEMENTS WERE PREPARED FOR THE TEN MONTH PERIOD FROM MARCH 2019 THROUGH DECEMBER 2019.